Selective Photoswitchable Allosteric Agonist of a G Protein-Coupled Receptor.

Selective Photoswitchable Allosteric Agonist of a G Protein-Coupled Receptor.
复制标题

G蛋白偶联受体的选择性光开关变构激动剂。

DOI:
10.1021/jacs.1c02586
复制
发表时间:
2021-06-23
影响因子:
15
通讯作者:
Isacoff EY
Isacoff EY
中科院分区:
化学1区
文献类型:
--
作者:
Donthamsetti P;Konrad DB;Hetzler B;Fu Z;Trauner D;Isacoff EY

文献摘要

参考文献

被引文献

相似文献

G 蛋白偶联受体 (GPCR) 是药物发现中最常见的目标。然而,相关GPCR之间的相似性加上体内受体激活的复杂时空动力学阻碍了药物开发。光药理学通过将可光致异构化的偶氮苯掺入 GPCR 配体中,提供了利用光来控制药物作用的位置和时间的可能性,从而实现非活性和活性构型之间的快速、可逆切换。该领域的最新进展包括(i)直接控制受体活性但非选择性的光激动剂和光拮抗剂,因为它们结合保守位点,以及(ii)选择性结合非保守位点但通过调节对内源配体的反应间接控制受体活性的光变构调节剂。在这项研究中,我们设计了一种光开关变构激动剂,它选择性地靶向非保守变构位点,并自行激活受体以提供直接控制。这项工作最终开发出了 aBINA,这是一种光开关变构激动剂,可选择性激活 Gi/o 偶联代谢型谷氨酸受体 2 (mGluR2)。 aBINA 是针对 GPCR 和其他临床重要信号蛋白的新型精准药物的第一个例子。
G protein-coupled receptors (GPCRs) are the most common targets of drug discovery. However, the similarity between related GPCRs combined with the complex spatiotemporal dynamics of receptor activation in vivo has hindered drug development. Photopharmacology offers the possibility of using light to control the location and timing of drug action by incorporating a photoisomerizable azobenzene into a GPCR ligand, enabling rapid and reversible switching between an inactive and active configuration. Recent advances in this area include (i) photoagonists and photoantagonists that directly control receptor activity but are nonselective because they bind conserved sites, and (ii) photoallosteric modulators that bind selectively to nonconserved sites but indirectly control receptor activity by modulating the response to endogenous ligand. In this study, we designed a photoswitchable allosteric agonist that targets a nonconserved allosteric site for selectivity and activates the receptor on its own to provide direct control. This work culminated in the development of aBINA, a photoswitchable allosteric agonist that selectively activates the Gi/o-coupled metabotropic glutamate receptor 2 (mGluR2). aBINA is the first example of a new class of precision drugs for GPCRs and other clinically important signaling proteins.
DOI: 10.1021/bc5003373
发表时间: 2014-10-15
影响因子: 4.7
作者:
Isabel Bahamonde, Maria;Taura, Jaume;Paoletta, Silvia;Gakh, Andrei A.;Chakraborty, Saibal;Hernando, Jordi;Fernandez-Duenas, Victor;Jacobson, Kenneth A.;Gorostiza, Pau;Ciruela, Francisco
通讯作者: Ciruela, Francisco
DOI: 10.1038/nrd2760
发表时间: 2009-01
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
通讯作者: --
DOI: 10.7554/elife.45116
发表时间: 2019-06-07
期刊: ELIFE
影响因子: 7.7
作者:
Gutzeit, Vanessa A.;Thibado, Jordana;Levitz, Joshua
通讯作者: Levitz, Joshua
DOI: 10.1111/bph.13065
发表时间: 2015-05-01
影响因子: 7.3
作者:
Farinha, A.;Lavreysen, H.;Tresadern, G.
通讯作者: Tresadern, G.
DOI: 10.1038/nrd.2017.178
发表时间: 2017-12
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
Hauser AS;Attwood MM;Rask-Andersen M;Schiöth HB;Gloriam DE
通讯作者: Gloriam DE